INVO Fertility, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 29 Apr 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Past financial statements no longer reliable (8-K Item 4.02)
The company stated in a Form 8-K (Item 4.02) filed on 02 Jun 2026 that previously issued financial statements should no longer be relied upon. This usually leads to a restatement of past results.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 01 Apr 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 18 May 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 17 Nov 2025, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →INVO Fertility, Inc. — Overview & Financial Snapshot
INVO Fertility, Inc. (NasdaqCM: IVF) is a Healthcare company, ranked #1,396 of 6,774 companies globally and #304 of 4,000 in United States on PositoAI, with a Positivity Score of 22,827. Its market capitalisation is ₹23.15 Cr ($2.45M), P/E ratio is 0.0 and P/B ratio is 0.15. It currently has 1 active red flag (PosiRed) and 4 yellow flags (PosiYellow, 10/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →